

Disclosures

Personal Commercial (12)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Abbott Laboratories	Research/Research Grants	Significant (>= \$5,000)	Invasive CV Angio and Interventions
Abbott Vascular	Consultant Fees/Honoraria	Significant (>= \$5,000)	Invasive CV Angio and Interventions
Baim Institute for Clinical Research	Salary	Significant (>= \$5,000)	Invasive CV Angio and Interventions General Cardiology
Boston Scientific	Consultant Fees/Honoraria	Significant (>= \$5,000)	Invasive CV Angio and Interventions
Boston Scientific	Research/Research Grants	Modest (< \$5,000)	General Cardiology
CathWorks	Consultant Fees/Honoraria	Modest (< \$5,000)	Noninvasive Imaging
Edwards	Consultant Fees/Honoraria	Modest (< \$5,000)	Invasive CV Angio and Interventions
Elixir Medical	Consultant Fees/Honoraria	Significant (>= \$5,000)	Invasive CV Angio and Interventions
Magenta Medical	Consultant Fees/Honoraria	Modest (< \$5,000)	Invasive CV Angio and Interventions
Medtronic	Research/Research Grants † SAFE PAD	Significant (>= \$5,000)	Vascular Medicine
Medtronic	Consultant Fees/Honoraria	Significant (>= \$5,000)	Stable Ischemic Heart Disease
Shockwave	Consultant Fees/Honoraria	Modest (< \$5,000)	Invasive CV Angio and Interventions

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (1)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
FDA	Salary	Modest (< \$5,000)	Other

Clinical Trial Enroller (1)

Trial Name	Trial Sponsor	Trial Funding Source
TARGET IV	MicroPort	

Institutional Financial Decision-Making Role (2)

Funding Source	Institutional Compensation Level
Beth Israel Deaconess Medical Center	Significant (>= \$5,000)
Richard and Susan Smith Center for Outcomes Research in Cardiology	Significant (>= \$5,000)

Expert Witness Testimony (3)

Year	Case Title	Represented	Description	Compensation
Self				
2024	Coronary intervention	Defendant		Significant (>= \$5,000)
2016	Coronary intervention	Defendant		Significant (>= \$5,000)
2015	Coronary artery disease	Defendant † Merck		Significant (>= \$5,000)

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 5/30/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 5/30/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 5/30/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 8/18/2025

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.